Implementing Precision Medicine in Best Practices of Chronic Airway Diseases

2019 ◽  
2020 ◽  
Vol 26 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Charlotte Suppli Ulrik ◽  
Susanne Vijverberg ◽  
Nicola A. Hanania ◽  
Zuzana Diamant

2016 ◽  
Vol 47 (2) ◽  
pp. 410-419 ◽  
Author(s):  
Alvar Agusti ◽  
Elisabeth Bel ◽  
Mike Thomas ◽  
Claus Vogelmeier ◽  
Guy Brusselle ◽  
...  

Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airway diseases that have a high personal and social impact. They likely represent a continuum of different diseases that may share biological mechanisms (i.e. endotypes), and present similar clinical, functional, imaging and/or biological features that can be observed (i.e. phenotypes) which require individualised treatment. Precision medicine is defined as “treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations”. In this Perspective, we propose a precision medicine strategy for chronic airway diseases in general, and asthma and COPD in particular.


2016 ◽  
Vol 04 (01) ◽  
pp. 10-15
Author(s):  
Kathleen Julia Silva ◽  
Giseli Domingues Cordeiro ◽  
Caroline Rossinoli ◽  
Maurício Longo Galhardo ◽  
Márcia Maria Faganello

Author(s):  
Demet Polat Yulug ◽  
Sibel Atış Naycı ◽  
Bahar Taşdelen ◽  
Eylem Sercan Ozgur ◽  
Cengiz Ozge

2020 ◽  
Vol 879 ◽  
pp. 173139 ◽  
Author(s):  
Li Hian Chin ◽  
Chian Ming Hon ◽  
Dinesh Kumar Chellappan ◽  
Jestin Chellian ◽  
Thiagarajan Madheswaran ◽  
...  

2019 ◽  
Vol 155 ◽  
pp. 66-71 ◽  
Author(s):  
Martina Flora ◽  
Fabio Perrotta ◽  
Ambra Nicolai ◽  
Rosalba Maffucci ◽  
Anna Pratillo ◽  
...  

Author(s):  
Jennifer L. Ersek ◽  
Lora J. Black ◽  
Michael A. Thompson ◽  
Edward S. Kim

There has been a rapid uptick in the pace of oncology precision medicine advancements over the past several decades as a result of increasingly sophisticated technology and the ability to study more patients through innovative trial designs. As more precision oncology approaches are developed, the need for precision medicine trials is increasing in the community setting, where most patients with cancer are treated. However, community-based practices, as well as some academic centers, may face unique barriers to implementing precision medicine programs and trials within their communities. Such challenges include understanding the tissue needs of molecular tests (e.g., tumor, blood), identifying which molecular tests are best used and when tissue should be tested, interpreting the test results and determining actionability, understanding the role of genetic counseling and/or follow-up testing, determining clinical trial eligibility, and assessing patient attitudes and financial concerns. The purpose of this article is to provide guidance to community-based oncology practices currently conducting clinical trials who want to expand their research program to include precision medicine trials. Here, we describe the core components of precision medicine programs and offer best practices for successful implementation of precision medicine trials in community-based practices.


Sign in / Sign up

Export Citation Format

Share Document